About Ankyrin repeat and SOCS box protein 4
Ankyrin repeat and SOCS box protein 4 (ASB4) is a protein
from Homo sapiens identified by UniProt accession
Q9Y574, 426 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Ankyrin repeat and SOCS box protein 4 |
| UniProt accession | Q9Y574 |
| Gene | ASB4 |
| Organism | Homo sapiens |
| Length | 426 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- mathematical ability · score 0.38
- body mass index · score 0.31
- self reported educational attainment · score 0.31
- body fat percentage · score 0.30
- pancreatic adenocarcinoma · score 0.18
- acute myeloid leukemia · score 0.10
- familial idiopathic steroid-resistant nephrotic syndrome · score 0.04
- focal segmental glomerulosclerosis · score 0.04
- hepatocellular carcinoma · score 0.04
- lung carcinoma · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y574-F1 | alphafold | PREDICTED | 92.69 | — |
Amino-acid sequence (426 residues)
MDGTTAPVTK SGAAKLVKRN FLEALKSNDF GKLKAILIQR QIDVDTVFEV EDENMVLASY KQGYWLPSYK LKSSWATGLH LSVLFGHVEC LLVLLDHNAT INCRPNGKTP LHVACEMANV DCVKILCDRG AKLNCYSLSG HTALHFCTTP SSILCAKQLV WRGANVNMKT NNQDEETPLH TAAHFGLSEL VAFYVEHGAI VDSVNAHMET PLAIAAYWAL RFKEQEYSTE HHLVCRMLLD YKAEVNARDD DFKSPLHKAA WNCDHVLMHM MLEAGAEANL MDINGCAAIQ YVLKVTSVRP AAQPEICYQL LLNHGAARIY PPQFHKVIQA CHSCPKAIEV VVNAYEHIRW NTKWRRAIPD DDLEKYWDFY HSLFTVCCNS PRTLMHLSRC AIRRTLHNRC HRAIPLLSLP LSLKKYLLLE PEGIIY
Explore Ankyrin repeat and SOCS box protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets